HOUSTON, Dec. 9, 2019 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biotechnology company specializing in the development of novel
treatments for brain tumors, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals, and Chris Downs,
Chief Financial Officer, will be attending the 8th Annual ROTH Deer
Valley Corporate Access Event at the Montage Deer Valley Hotel in
Park City, Utah.
Event:
|
8th Annual ROTH Deer
Valley Corporate Access Event
|
Format:
|
Small Group & 1x1
Meetings
|
Date:
|
December 11-12,
2019
|
Location:
|
Montage Deer Valley
Hotel, Park City, Utah
|
About Berubicin
Berubicin is an anthracycline, a class
of drugs among the most powerful chemotherapy drugs and effective
against more types of cancer than any other class of
chemotherapeutic agents. Anthracyclines are designed to damage the
DNA of targeted cancer cells by interfering with the action of the
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin was developed at the MD Anderson Cancer Center (MDACC),
the world's largest cancer research facility. Berubicin appeared to
demonstrate one Durable Complete Response in a Phase I human
clinical trial conducted by a prior developer.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company specializing in the
development of novel treatments for primary and metastatic brain
and central nervous system tumors. Its lead candidate Berubicin is
for the treatment of glioblastoma, a type of brain cancer currently
considered incurable, as well as pancreatic and ovarian cancers,
and lymphomas. The Company entered into an IP agreement with
Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata
Pharmaceuticals, Inc. For more information, visit
www.cnspharma.com
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-the-8th-annual-roth-deer-valley-corporate-access-event-300970789.html
SOURCE CNS Pharmaceuticals, Inc.